MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

35.78 0.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

34.82

Max

36.09

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	12.073 87.826
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+14.32% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	517M 2.2B
Ankstesnė atidarymo kaina	35.19
Ankstesnė uždarymo kaina	35.78

Naujienos nuotaikos

By Acuity

35%

65%

120 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-13 19:05; UTC

Pagrindinės rinkos jėgos

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

2026-01-13 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Japan Election Hopes -- Market Talk

2026-01-13 23:41; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-13 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

2026-01-13 23:13; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

2026-01-13 23:10; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

2026-01-13 23:03; UTC

Rinkos pokalbiai

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

2026-01-13 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

2026-01-13 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

2026-01-13 21:15; UTC

Įsigijimai, susijungimai, perėmimai

VERSANT Completes Acquisition Of Free TV Networks >VSNT

2026-01-13 21:08; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

2026-01-13 20:39; UTC

Rinkos pokalbiai

Silver Settles at Another New High -- Market Talk

2026-01-13 20:21; UTC

Rinkos pokalbiai

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

2026-01-13 20:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

2026-01-13 19:08; UTC

Įsigijimai, susijungimai, perėmimai

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

2026-01-13 19:03; UTC

Uždarbis

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

2026-01-13 18:50; UTC

Uždarbis

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

2026-01-13 17:54; UTC

Rinkos pokalbiai

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

2026-01-13 17:49; UTC

Rinkos pokalbiai

Analysts Call For Potential Record Ethanol Output -- Market Talk

2026-01-13 17:38; UTC

Rinkos pokalbiai

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 17:19; UTC

Rinkos pokalbiai

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

2026-01-13 17:15; UTC

Rinkos pokalbiai

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

14.32% į viršų

12 mėnesių prognozė

Vidutinis 43.75 USD 14.32%

Aukščiausias 55 USD

Žemiausias 32 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

120 / 361 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.